和邦生物股价震荡，回应光伏资产减值疑虑

Core Viewpoint - The stock price of Hebang Bio (603077) has shown volatility, with a recent increase followed by a decline, indicating mixed market sentiment and performance [1][2]. Group 1: Stock Performance - On February 11, 2026, the stock price increased by 2.04% to 2.50 CNY per share, with a net inflow of 2.28 million CNY, but closed at 2.47 CNY, a daily increase of 0.82% [1]. - As of February 13, 2026, the stock price fell by 2.86% to 2.38 CNY per share, with a trading volume of 477 million CNY and a turnover rate of 2.25% [1]. - The stock has a cumulative decline of 2.46% over the past five days but has increased by 5.31% year-to-date [1]. Group 2: Recent Announcements - On February 12, 2026, Hebang Bio responded to a shareholder inquiry regarding potential impairment of photovoltaic assets, stating that as of June 30, 2024, there were no signs of impairment for the Chongqing Wujun photovoltaic project and Fuyang silicon wafer project, with future cash flow present value exceeding book value [2]. - On February 13, 2026, the company announced a plan to purchase 6,500 tons of soda ash from an affiliated party for 66.15 million CNY at a price of 1,017.70 CNY per ton, aimed at optimizing the supply chain [2]. - The total amount of similar related-party transactions in the past 12 months reached 94.98 million CNY, accounting for less than 1% of net assets [2]. Group 3: Institutional Sentiment - As of February 14, 2026, institutional sentiment is neutral, with 100% of ratings being neutral and no clear bullish or bearish tendencies [3]. - Two institutions forecast a 6.85% year-on-year increase in net profit for 2025, with expected revenue of 12.915 billion CNY [3]. - Market attention is generally low, with infrequent research activity and no significant adjustments to target prices [3].